Catabasis Wins With Early-Stage Duchenne Muscular Dystrophy Study

Health and Healthcare

Published: November 27, 2018 1:40 pm

Last Updated: January 11, 2020 2:27 pm

Catabasis Pharmaceuticals Inc. (NASDAQ: CATB) shares made a handy gain on Tuesday after the company announced early stage data from its Duchenne muscular dystrophy (DMD) study.

The company announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases.

Overall edasalonexent was well tolerated in pediatric patients and the data demonstrated that edasalonexent inhibited NF-kB in pediatric patients with DMD. NF-kB is a key link between loss of dystrophin and disease progression in DMD.

MoveDMD is a multipart trial including Phase 1, Phase 2 and an ongoing open-label extension. Catabasis is currently enrolling the Phase 3 PolarisDMD trial for edasalonexent.

The Phase 1 MoveDMD results demonstrated:

Edasalonexent was well tolerated, with all patients completing the 1-week study without serious adverse events or dose reductions and with no safety signals

Edasalonexent was rapidly absorbed, with peak levels observed 2-6 hours after dosing and exposure was dose-dependent

After 7 days of treatment, NF-kB-regulated genes were significantly decreased in a dose-dependent manner, confirming that edasalonexent inhibited NF-kB in boys with DMD

Erika Finanger, M.D., Associate Professor of Pediatrics, Division of Neurology, School of Medicine at Oregon Health & Science University and principal investigator for both the MoveDMD and PolarisDMD trials, commented:

The data from the Phase 1 MoveDMD trial reinforce the good tolerability and safety profile of edasalonexent that we have now also observed in the Phase 2 trial and open-label extension. I am pleased to continue to evaluate edasalonexent as a potential novel therapy for those affected by Duchenne, and I am excited to participate in the Phase 3 PolarisDMD study.

The primary objective of the Phase 1 portion of the MoveDMD trial was to assess the safety and tolerability of edasalonexent, with the secondary objective to assess the PK and target engagement of edasalonexent in pediatric patients with DMD to provide guidance in the Phase 2 portion of the study.

Shares of Catabasis were last seen up about 4% at $0.60, in a 52-week range of $0.53 to $2.38. The stock has a consensus analyst price target of $3.83.

ALSO READ: Jefferies Has Huge Contrarian Semiconductor Call: 5 Stocks to Buy Now

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps